MXPA02001764A - Compuestos heteropoliciclicos y su uso como antagonistas de receptor de glutamato metabotropico. - Google Patents

Compuestos heteropoliciclicos y su uso como antagonistas de receptor de glutamato metabotropico.

Info

Publication number
MXPA02001764A
MXPA02001764A MXPA02001764A MXPA02001764A MXPA02001764A MX PA02001764 A MXPA02001764 A MX PA02001764A MX PA02001764 A MXPA02001764 A MX PA02001764A MX PA02001764 A MXPA02001764 A MX PA02001764A MX PA02001764 A MXPA02001764 A MX PA02001764A
Authority
MX
Mexico
Prior art keywords
metabotropic glutamate
receptor antagonists
glutamate receptor
heteropolycyclic compounds
group
Prior art date
Application number
MXPA02001764A
Other languages
English (en)
Inventor
Wagenen Bradford C Van
Original Assignee
Nps Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22530400&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA02001764(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nps Pharma Inc filed Critical Nps Pharma Inc
Publication of MXPA02001764A publication Critical patent/MXPA02001764A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Los compuestos de formula (II), en donde X, Y y Z son seleccionados independientemente del grupo que consiste de N, O, S, C y CO, en donde al menos uno de X, Y y Z es un heteroatomo; Ar1 y Ar2 son seleccionados independientemente del grupo que consiste de porcion heterociclica o heterociclica fusionada y una porcion aromatica; actuan como antagonistas en receptores de glutamato metabotropico y son utiles para tratar enfermedades y desordenes neurologicos. (Ver Formula).
MXPA02001764A 1999-08-19 2000-08-18 Compuestos heteropoliciclicos y su uso como antagonistas de receptor de glutamato metabotropico. MXPA02001764A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14946499P 1999-08-19 1999-08-19
PCT/US2000/022618 WO2001012627A1 (en) 1999-08-19 2000-08-18 Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists

Publications (1)

Publication Number Publication Date
MXPA02001764A true MXPA02001764A (es) 2004-03-19

Family

ID=22530400

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02001764A MXPA02001764A (es) 1999-08-19 2000-08-18 Compuestos heteropoliciclicos y su uso como antagonistas de receptor de glutamato metabotropico.

Country Status (28)

Country Link
EP (1) EP1210344B1 (es)
JP (2) JP3790472B2 (es)
KR (1) KR100875222B1 (es)
CN (1) CN1313465C (es)
AT (1) ATE307129T1 (es)
AU (1) AU780191B2 (es)
BG (1) BG65586B1 (es)
BR (1) BR0013427A (es)
CA (1) CA2381975A1 (es)
CY (1) CY1105253T1 (es)
CZ (1) CZ2002599A3 (es)
DE (1) DE60023318T2 (es)
DK (1) DK1210344T3 (es)
EE (1) EE200200079A (es)
ES (1) ES2250177T3 (es)
HK (1) HK1047929A1 (es)
HU (1) HUP0202757A3 (es)
IL (2) IL148157A0 (es)
IS (1) IS6275A (es)
MX (1) MXPA02001764A (es)
NO (1) NO322460B1 (es)
NZ (1) NZ517221A (es)
PL (1) PL353825A1 (es)
RU (1) RU2296127C9 (es)
SK (1) SK2512002A3 (es)
UA (1) UA75871C2 (es)
WO (1) WO2001012627A1 (es)
ZA (1) ZA200201358B (es)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
BR0207390A (pt) * 2001-02-21 2004-10-13 Nps Pharma Inc Compostos, composições farmacêuticas e métodos de tratatamento de doença associada a ativação e a ativação do grupo i mg1ur
EP1392363B1 (en) * 2001-04-02 2006-09-20 Brown University Research Foundation Use of mGLuR5 antagonists in the manufacture of a medicament in the treatment of Fragile X syndrome, Autism and Mental Retardation
US6916821B2 (en) 2001-04-02 2005-07-12 Brown University Methods of treating disorders with Group I mGluR antagonists
AU2002359714B2 (en) * 2001-12-18 2006-12-21 Merck Sharp & Dohme Corp. Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
ATE374194T1 (de) * 2001-12-18 2007-10-15 Merck & Co Inc Heteroarylsubstituierte triazolmodulatoren des metabotropen glutamatarezeptors 5
JP2005516950A (ja) * 2001-12-19 2005-06-09 メルク　エンド　カムパニー　インコーポレーテッド 代謝型グルタミン酸受容体−５のヘテロアリール置換イミダゾールモジュレータ
WO2003077918A1 (en) * 2002-03-12 2003-09-25 Merck & Co., Inc. Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5
US7964609B2 (en) 2002-06-20 2011-06-21 Astrazeneca Ab Use of mGluR5 antagonists for the treatment of gerd
SE0201943D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab New use
TW200812986A (en) * 2002-08-09 2008-03-16 Nps Pharma Inc New compounds
RU2352568C9 (ru) 2002-08-09 2009-06-27 Астразенека Аб [1,2,4]оксадиазолы (варианты), способ их получения, фармацевтическая композиция и способ ингибирования активации метаботропных глютаматных рецепторов-5
MXPA05001590A (es) * 2002-08-09 2005-05-23 Astrazeneca Ab Compuestos que tienen actividad en los receptores metabotropicos de glutamato.
GB0303503D0 (en) * 2003-02-14 2003-03-19 Novartis Ag Organic compounds
AU2004227833B2 (en) * 2003-04-04 2009-10-01 Merck & Co., Inc. Di-aryl substituted triazole modulators of metabotropic glutamate receptor-5
EP1625123A4 (en) * 2003-05-15 2007-08-29 Merck & Co Inc 3- (2-AMINO-1-AZACYCLYL) -5-ARYL-1,2,4-OXADIAZOLE AS S1P RECEPTOR AGONISTS
WO2005060961A2 (en) * 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd)
JP4958560B2 (ja) * 2003-12-24 2012-06-20 プロシディオン・リミテッド Ｇｐｃｒ受容体作動薬としてのヘテロ環誘導体
ES2309718T3 (es) * 2004-02-18 2008-12-16 Astrazeneca Ab Compuestos heterociclicos condensados y su uso como antagonistas de los receptores metabotropicos para el tratamiento de trastornos gastrointestinales.
US7585881B2 (en) * 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
TW200538108A (en) 2004-02-19 2005-12-01 Astrazeneca Ab Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
US7858800B2 (en) * 2004-06-30 2010-12-28 Banyu Pharmaceutical Co., Ltd. Biaryl derivatives
KR100621192B1 (ko) * 2004-10-13 2006-09-19 한국화학연구원 무스카린 수용체 작용물질로서 작용하는1,2,3,4-테트라하이드로피리미디닐-1,2,4-옥사다이아졸유도체와 이의 제조방법
JP4557685B2 (ja) 2004-11-15 2010-10-06 独立行政法人理化学研究所 蛍光蛋白質
CA2593439C (en) 2005-01-14 2014-02-25 F. Hoffmann-La Roche Ag Thiazole-4-carboxamide derivatives as mglur5 antagonists
GB0510142D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
WO2007001973A1 (en) * 2005-06-28 2007-01-04 Astrazeneca Ab New use
KR101370280B1 (ko) 2005-07-26 2014-03-06 바이알 - 포르텔라 앤드 씨에이 에스에이 Ｃｏｍｔ 억제제로서의 니트로카테콜 유도체
AR058807A1 (es) 2005-09-29 2008-02-27 Astrazeneca Ab 5-(fenilisoxazoletoxi)-triazol-3-il piridinas sustituidas, para el tratamiento de trastornos mediados por el receptor mglur5
KR101020431B1 (ko) 2005-11-08 2011-03-08 에프. 호프만-라 로슈 아게 ｍＧｌｕＲ5 수용체 길항제로서의 티아졸로[4,5-c]피리딘 유도체
US7951824B2 (en) 2006-02-17 2011-05-31 Hoffman-La Roche Inc. 4-aryl-pyridine-2-carboxyamide derivatives
MX356221B (es) * 2006-04-03 2018-05-18 Astellas Pharma Inc Heterocompuesto.
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
EP2083921A2 (en) * 2006-09-04 2009-08-05 Neurosearch A/S Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
JP5253401B2 (ja) 2006-09-07 2013-07-31 アクテリオン ファーマシューティカルズ リミテッド 免疫調節薬としてのピリジン−４−イル誘導体
NZ576059A (en) 2006-09-08 2012-03-30 Actelion Pharmaceuticals Ltd Pyridin-3-yl derivatives as immunomodulating agents
WO2008035239A1 (en) 2006-09-21 2008-03-27 Actelion Pharmaceuticals Ltd Phenyl derivatives and their use as immunomodulators
JP5517629B2 (ja) 2007-01-31 2014-06-11 ノヴィファーマ，エス．アー． Ｃｏｍｔ阻害剤用の投薬計画
NZ580454A (en) 2007-03-16 2011-05-27 Actelion Pharmaceuticals Ltd Amino- pyridine derivatives as s1p1 /edg1 receptor agonists
SI2195311T1 (sl) 2007-08-17 2011-07-29 Actelion Pharmaceuticals Ltd Derivati piridina kot modulatorji receptorja s1p1/edg1
AU2008319308B2 (en) 2007-10-31 2013-01-31 Merck Sharp & Dohme Corp. P2X3, receptor antagonists for treatment of pain
AR069146A1 (es) 2007-11-01 2009-12-30 Actelion Pharmaceuticals Ltd Derivados de pirimidina, composicion farmaceutica que los comprende y el uso de esta para el tratamiento de enfermedades relacionadas con la activacion del sistema inmunitario.
SI2234985T1 (sl) * 2007-12-20 2012-06-29 Bayer Pharma AG 4-(4-ciano-2-tioaril)dihidropirimidinoni in njihova uporaba
WO2009100438A2 (en) 2008-02-07 2009-08-13 Massachusetts Eye & Ear Infirmary Compounds that enhance atoh-1 expression
WO2009109904A1 (en) 2008-03-07 2009-09-11 Actelion Pharmaceuticals Ltd Novel aminomethyl benzene derivatives
RU2010139315A (ru) 2008-03-17 2012-04-27 Биал - Портела Энд Ка., С.А. (Pt) Кристаллические формы 5-[3-(2,5-дихлор-4,6-диметил-1-окси-пиридин-3-ил)[1,2,4]оксадиазол-5-ил]-3-нитробензол-1,2-диола
EP2860178B1 (en) 2008-10-31 2021-01-13 Merck Sharp & Dohme Corp. P2X3 receptor antagonists for treatment of pain
DE102008057343A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung
DE102008057364A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Substituierte Aryl-Verbindungen und ihre Verwendung
DE102008057344A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Aminoalkyl-substituierte Aryl-Verbindungen und ihre Verwendung
DE102009041242A1 (de) 2009-09-11 2011-12-15 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung
DE102009041241A1 (de) 2009-09-11 2011-08-04 Bayer Schering Pharma Aktiengesellschaft, 13353 Substituierte Aryl-Verbindungen und ihre Verwendung
EP2410858B1 (en) 2009-03-23 2016-09-07 Merck Sharp & Dohme Corp. P2x3 receptor antagonists for treatment of pain
ES2660892T3 (es) 2009-03-23 2018-03-26 Merck Sharp & Dohme Corp. Antagonistas del receptor P2X3 para el tratamiento del dolor
WO2010111058A1 (en) 2009-03-23 2010-09-30 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
ES2730678T3 (es) 2009-04-01 2019-11-12 Bial Portela & Ca Sa Formulaciones farmacéuticas que comprenden derivados de nitrocatecol y métodos para fabricarlas
EP2419412A1 (en) * 2009-04-13 2012-02-22 Irm Llc Compositions and methods for modulating retinol binding to retinol binding protein 4 (rbp4)
DK2454255T3 (da) 2009-07-16 2013-12-16 Actelion Pharmaceuticals Ltd Pyridin-4-ylderivater som s1p1/edg1-agonister
WO2011109398A2 (en) 2010-03-02 2011-09-09 President And Fellows Of Harvard College Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
MY163185A (en) 2011-01-19 2017-08-15 Idorsia Pharmaceuticals Ltd 2-methoxy-pyridin-4-yl derivatives
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
ES2960805T3 (es) 2011-12-13 2024-03-06 Bial Portela & Ca Sa Compuesto químico útil como intermediario para preparar un inhibidor de catecol-o-metiltransferasa
JP5946288B2 (ja) * 2012-02-24 2016-07-06 公立大学法人名古屋市立大学 新規ヒドロキサム酸誘導体及びその用途
EA029853B1 (ru) * 2013-02-15 2018-05-31 Монсанто Текнолоджи Ллс 3,5-дизамещенные-4,5-дигидро-1,2,4-оксадиазолы для борьбы с нематодными вредителями
EP2853532B1 (en) * 2013-09-28 2020-12-09 Instytut Farmakologii Polskiej Akademii Nauk 1,2,4-oxadiazole derivatives as allosteric modulators of metabotropic glutamate receptors belonging to group III
WO2016083863A1 (en) 2014-11-28 2016-06-02 Bial - Portela & Ca, S.A. Medicaments for slowing parkinson's disease
HUE047646T2 (hu) 2015-05-20 2020-05-28 Idorsia Pharmaceuticals Ltd Az (S)-3-{4-[5-(2-ciklopentil-6-metoxi-piridin-4-il)-[1,2,4]oxadiazol-3-il]-2-etil-6-metil-fenoxi} -propán-1,2-diol vegyület kristályformája
BR112017028125A2 (pt) 2015-06-23 2018-08-28 Kissei Pharmaceutical Co., Ltd. derivado de pirazola ou sal farmaceuticamente aceitável do mesmo
WO2017171594A1 (en) * 2016-03-30 2017-10-05 Tadeusz Wieloch Negative allosteric modulators of mglur5 for use in the treatment of mature brain damages.
KR102276327B1 (ko) * 2019-06-25 2021-07-12 연세대학교 산학협력단 신규 옥사다이아졸 화합물 및 이를 포함하는 당뇨 예방 또는 치료용 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1149011B (de) * 1960-04-05 1963-05-22 Hoechst Ag Verfahren zur Herstellung von 3, 5-disubstituierten 1, 2, 4-Oxdiazolen
US3647809A (en) * 1968-04-26 1972-03-07 Chinoin Gyogyszer Es Vegyeszet Certain pyridyl-1 2 4-oxadiazole derivatives
US4003909A (en) * 1974-07-22 1977-01-18 E. R. Squibb & Sons, Inc. [(1,2,4-Oxadiazol-3-yl)phenyl]carbamic or thiocarbamic acid esters
US4022901A (en) * 1975-03-05 1977-05-10 E. R. Squibb & Sons, Inc. 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles
AU675484B2 (en) * 1993-03-24 1997-02-06 Neurosearch A/S Benzimidazole compounds, their use and preparation
US5554630A (en) * 1993-03-24 1996-09-10 Neurosearch A/S Benzimidazole compounds
WO1994022846A1 (en) * 1993-03-30 1994-10-13 Pfizer Inc. Compounds enhancing antitumor activity of other cytotoxic agents
EE04310B1 (et) * 1995-04-21 2004-06-15 Neurosearch A/S Bensimidasooli ühendid, neid ühendeid sisaldavad farmatseutilised kompositsioonid ja nende kasutamine
AU6526896A (en) * 1995-07-22 1997-02-18 Rhone-Poulenc Rorer Limited Substituted aromatic compounds and their pharmaceutical use
DE19643037A1 (de) * 1996-10-18 1998-04-23 Boehringer Ingelheim Kg Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
MXPA00004940A (es) * 1997-11-21 2002-10-17 Nps Pharma Inc Antagonistas de receptor de glutamato metabotropico para tratar enfermedades del sistema nervioso central.

Also Published As

Publication number Publication date
CN1379775A (zh) 2002-11-13
DE60023318T2 (de) 2006-07-20
ATE307129T1 (de) 2005-11-15
JP2003507378A (ja) 2003-02-25
NZ517221A (en) 2004-01-30
EP1210344B1 (en) 2005-10-19
BG106493A (en) 2003-01-31
CA2381975A1 (en) 2001-02-22
AU6782400A (en) 2001-03-13
NO20020823L (no) 2002-04-17
SK2512002A3 (en) 2002-07-02
PL353825A1 (en) 2003-12-01
EP1210344A1 (en) 2002-06-05
NO20020823D0 (no) 2002-02-19
KR20020038731A (ko) 2002-05-23
ES2250177T3 (es) 2006-04-16
JP3790472B2 (ja) 2006-06-28
BR0013427A (pt) 2002-07-30
IL148157A (en) 2007-07-04
DK1210344T3 (da) 2006-03-06
CN1313465C (zh) 2007-05-02
JP2006143746A (ja) 2006-06-08
HK1047929A1 (en) 2003-03-14
EE200200079A (et) 2003-06-16
HUP0202757A2 (hu) 2002-12-28
RU2296127C9 (ru) 2007-08-27
DE60023318D1 (de) 2006-03-02
RU2296127C2 (ru) 2007-03-27
IL148157A0 (en) 2002-09-12
KR100875222B1 (ko) 2008-12-19
HUP0202757A3 (en) 2006-03-28
IS6275A (is) 2002-02-18
UA75871C2 (en) 2006-06-15
AU780191B2 (en) 2005-03-03
NO322460B1 (no) 2006-10-09
CZ2002599A3 (cs) 2002-06-12
ZA200201358B (en) 2003-07-30
BG65586B1 (bg) 2009-01-30
CY1105253T1 (el) 2010-03-03
WO2001012627A1 (en) 2001-02-22

Similar Documents

Publication Publication Date Title
MXPA02001764A (es) Compuestos heteropoliciclicos y su uso como antagonistas de receptor de glutamato metabotropico.
LU92113I2 (fr) Perampanel et ses dérivés pharmaceutiquement acceptables (FYCOMPA)
DE69820632D1 (de) 2-phenyl-substituierte 1-(n-phenylaminoalkyl)-piperazin-derivate
NO20060219L (no) Forbindelser
NO996178L (no) 4-aminopyrrol(3,2-d)pyrimidiner som neuropeptid y- reseptorantagonister
MXPA03001186A (es) Compuestos heterociclicos como ligandos del receptor acido gamma aminobutirico (gabaa).
DE60210944D1 (de) N-substituierte heterocyclische nichtaryl-nmda/nr2b-antagonisten
EA200100203A1 (ru) Производные 4,4-биарилпиперидина с активностью в отношении опиоидных рецепторов
TR200102489T2 (tr) 3-Fenilpiridin Türevleri ve bunların NK-1 alıcı antagonistler olarak kullanılması
BR9711342A (pt) Antagonistas de receptor de bombesina nÆo-pept¡do
TR200201684T2 (tr) Fenilpiperazinil türevleri
EA200301143A1 (ru) Производные гетероциклилалкокси-, алкилтио- и -алкиламинобензазола в качестве лигандов 5-гидрокситриптамина-6
FR2767527B1 (fr) Derives de piperazines indoliques, utiles comme medicaments et procede de preparation
WO2002014294A3 (en) Heterocyclic sulfonamide derivatives and their use for potentiating glutamate receptor function
CA2388470A1 (en) Use of carbonylamino derivatives against cns disorders
DE69812010D1 (de) 4-Aminopyrrole (3,2-d) Pyrimidinen als Antagonisten des Neuropeptide Y Receptors
EP1582519A3 (en) Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
EP1172106A3 (en) Use of fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles as substance P receptor antagonists
RS50449B (sr) Supstituisani bisindolilmaleimidi za inhibiciju proliferacije ćelija
ES2102837T3 (es) 4-amino-2-(hetero)aril-butanamidas utiles como antagonistas de los receptores de 5-ht1a.
ES2127699A1 (es) Nuevos derivados de 2,3-benzodiazepina.
YU38498A (sh) Derivati 2-(arilfenil)amino-imidazolina

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights